Dynogen Pharmaceuticals, Inc.

52 Second Avenue
Waltham, MA 02451

TEL: 781-839-5100
FAX: 781-839-5200

www.dynogen.com

PRESS RELEASE

For information contact:
Mark Boshar
Dynogen Pharmaceuticals, Inc.
(781) 839-5114

Media:
Kari Lampka
MacDougall BioCommunications, Inc.
(508) 647-0209, ext. 11
kari@macbiocom.com

DYNOGEN AWARDED BROAD U.S. PATENT RELATING TO TREATMENT OF LOWER URINARY TRACT DISORDERS

- Patent Highlights Company's Ability to Discover Additional Therapeutic Uses for Drug Candidates -

WALTHAM, Mass., January 25, 2005 – Dynogen Pharmaceuticals, Inc. announced today that it has been awarded United States Patent No. 6,846,823 (the '823 patent) related to the use of DDP225, formerly known as MCI225, for the treatment of lower urinary tract disorders. The claims of this patent cover the use of a broad class of thieno[2,3-d]pyrimidine derivatives, including DDP225, for the treatment of urinary frequency, urinary urgency, nocturia (nighttime urination) and enuresis (bedwetting). These symptoms are associated with overactive bladder (OAB), the irritative symptoms of benign prostatic hyperplasia (BPH), interstitial cystitis and other lower urinary tract disorders. Dynogen is studying DDP225 in human clinical trials for irritable bowel syndrome with diarrhea (IBS-d), and has applied its expertise in predictive pharmacology to identify other potential indications for this compound, including those covered in the '823 patent.

"By studying this compound in our predictive pharmacology platform, we have rapidly expanded the commercial potential for DDP225 by identifying and protecting its use in multiple therapeutic areas, including GU and GI disorders," said Lee R. Brettman, M.D., Chief Executive Officer at Dynogen. "We believe that this type of value creation is exactly what Dynogen provides with its scientific expertise and portfolio creation strategy in the area of neuroscience-based GU and GI treatments."

– more –

DDP225 is both a serotonin receptor antagonist and noradrenaline reuptake inhibitor (NARI). Serotonin and noradrenaline are neurotransmitters that are known to be involved in the control of both genitourinary (GU) and gastrointestinal (GI) systems. Serotonin acts on discrete serotonin receptors. Currently there are fourteen subtypes of such receptors delineated into seven families. DDP225 is a serotonin type 3 (5-HT3) antagonist. NARIs inhibit noradrenaline transporter function and, as such, result in an increase in the concentration of noradrenaline in the synapse. Dynogen's preclinical studies have shown that selective targeting of both these mechanisms may lead to promising new treatments for GU and GI disorders.

In addition to protection offered by broad claims which define thieno[2,3-d]pyrimidine derivatives structurally , the claims of this patent also protect the mechanisms of action by covering the use of any $5\text{-}HT_3$ receptor antagonist in combination with any NARI for the treatment of frequency, urgency, nocturia and enuresis.

"We have taken a very aggressive approach to building a broad patent estate around our development candidates, such as DDP225, in multiple therapeutic areas," said Mark Boshar, Vice President of Legal Affairs and Chief Patent Counsel at Dynogen. "Our success in rapidly breathing new patent life into this exciting compound provides strong validation for an important component of Dynogen's patent strategy," he added.

DDP225 was previously studied by Mitsubishi Pharma Corporation in Phase II clinical trials for depression and Alzheimer's disease. As part of its strategy to rapidly and efficiently build a pipeline with a greater likelihood for clinical success, Dynogen licensed DDP225 and all related preclinical and clinical data from Mitsubishi Pharma in October 2003. Access to Phase II safety and pharmacokinetic study results in combination with GU and GI data generated by Dynogen's predictive pharmacology platform will allow Dynogen to reduce the clinical development risk and development time for this product candidate.

About Dynogen Pharmaceuticals, Inc.

Dynogen is a privately held, neuroscience-based pharmaceutical company developing more effective treatments for genitourinary (GU) and gastrointestinal (GI) disorders. The company is leveraging its understanding of the nexus between neurology and GU and GI disorders with a predictive pharmacology platform to rapidly build a high value pipeline of drugs with a greater likelihood for clinical success. More information about the company can be found by visiting our new website www.dynogen.com.

# # #